NICE releases draft guidance on Olumiant for rheumatoid arthritis
UK medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has today published draft guidance recommending US pharma major Eli Lilly’s (NYSE: LLY) Olumiant (baricitinib) for some people with rheumatoid arthritis (RA).
The draft guidance recommends baricitinib as an option for treating severe active RA in adults whose disease hasresponded inadequately to intensive therapy with conventional disease-modifying antirheumatic drugs (DMARDs). It is also recommended in adults who have had an inadequate response to, or who cannot have other DMARDs, including at least one biological DMARD.
The NICE noted that Eli Lilly has agreed a patient access scheme that will reduce the cost of baricitinib to the National Health Service. The details of the scheme are commercial in confidence.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze